When depression has not improved after trying standard antidepressants, the next step can feel frustratingly unclear. Understanding how Spravato treatment works can make that decision easier, especially for patients and families who want a medically supervised option with a different mechanism than traditional oral medication.
Spravato is the brand name for esketamine, a prescription nasal spray approved by the FDA for adults with treatment-resistant depression and, in some cases, major depressive disorder with acute suicidal thoughts or actions. It is not a first-line treatment, and it is not something patients take at home. It is given in a certified medical setting under close supervision because safety, monitoring, and the right patient selection matter.
How Spravato treatment works in the brain
Most standard antidepressants focus on neurotransmitters such as serotonin, norepinephrine, or dopamine. Spravato works differently. Esketamine acts on the brain’s glutamate system, specifically through NMDA receptor activity. That difference is a major reason it may help some patients who have not responded well to more conventional medications.
Glutamate is the brain’s most abundant excitatory neurotransmitter. It plays a central role in communication between nerve cells, learning, memory, and the brain’s ability to adapt. In depression, especially long-standing or treatment-resistant depression, those signaling pathways may not function as efficiently as they should. Spravato appears to trigger a cascade of changes that can help restore synaptic connections and improve communication in brain networks involved in mood regulation.
That does not mean the treatment is instant or identical for everyone. Some patients notice improvement relatively quickly, while others need time and a full induction course before meaningful changes show up. The goal is breakthrough relief, but the pace and degree of benefit can vary.
Why Spravato is different from standard antidepressants
One reason patients ask about Spravato is timing. Traditional antidepressants can take several weeks to show full effect. Spravato may work faster for some individuals, which is especially relevant when depression is severe and daily functioning has been heavily affected.
Another difference is how it is used. Spravato is typically prescribed alongside an oral antidepressant rather than replacing all other treatment. It is part of a broader care plan, not a standalone shortcut. That plan may also include psychiatric follow-up, medication management, and therapy depending on the patient’s needs.
There are trade-offs. Because Spravato can cause temporary side effects such as dissociation, dizziness, sedation, nausea, or increased blood pressure, each session requires observation after dosing. Patients need transportation home and should not drive the same day. For many people, that extra structure is worth it because it adds a layer of safety and allows the treatment team to respond quickly if concerns arise.
Who may be a good candidate
Spravato is generally considered for adults with treatment-resistant depression, which usually means depression that has not responded adequately after trying at least two antidepressants at appropriate doses and duration. It may also be considered in certain urgent depressive situations under FDA-approved indications.
Candidacy is never based on diagnosis alone. A psychiatric evaluation helps determine whether Spravato is clinically appropriate and safe. Your psychiatrist will look at your symptom history, previous medication trials, co-occurring conditions, substance use history, blood pressure concerns, and current medications. This matters because a treatment can be promising on paper and still not be the right fit for a specific patient.
For example, some individuals with uncontrolled hypertension, certain vascular conditions, or active substance misuse may need a different plan. Others may be excellent candidates because they have tried multiple antidepressants, tolerated treatment well overall, and still remain stuck with significant depressive symptoms.
What happens before the first session
Before starting Spravato, patients complete a structured medical and psychiatric assessment. This is where expectations become practical. The care team confirms diagnosis, reviews prior treatment response, explains risks and benefits, and outlines the monitoring process.
Insurance approval and treatment scheduling are often part of this stage too. Since Spravato is given in a certified clinic, treatment is organized around supervised visits rather than a standard pharmacy pickup. Patients are also instructed not to eat for at least two hours before treatment and to avoid drinking liquids for 30 minutes before dosing to reduce the chance of nausea.
This preparation may feel more involved than starting a typical antidepressant, but it is designed to support safety and better outcomes. In a specialty psychiatric setting, patients usually find that the extra planning reduces uncertainty.
What a Spravato appointment is actually like
For many patients, the biggest question is not the science. It is what the session feels like.
At the appointment, vital signs are checked before treatment begins. The nasal spray is self-administered under the guidance of trained medical staff, usually in a calm outpatient environment. After the dose, the patient remains in the clinic for observation for at least two hours.
During that monitoring period, some patients feel relaxed, detached, sleepy, or mildly dizzy. Others describe a floating sensation or changes in perception that fade as the medication wears off. These effects are expected and are one reason treatment must occur under supervision. Staff continue monitoring blood pressure, symptoms, and overall tolerance throughout the visit.
Most patients are able to go home afterward with a responsible adult driving them. The rest of the day is usually reserved for rest. Work, school, major decisions, and driving should wait until the following day after a full night’s sleep.
How often treatment is given
The schedule usually starts with an induction phase, followed by a maintenance phase. In the first month, Spravato is often given twice weekly. After that, visits may decrease to once weekly and then every other week depending on response and clinical judgment.
This tapering structure allows the treatment team to balance effectiveness with practicality. Some patients do well with less frequent maintenance. Others need a more individualized schedule because symptoms return when sessions are spaced too far apart. That is why ongoing psychiatric oversight is essential.
A treatment plan should never be one-size-fits-all. The frequency, duration, and accompanying therapies depend on how the patient is doing, what side effects show up, and whether functional improvement is happening in daily life.
How Spravato treatment works as part of a larger care plan
Spravato can be a powerful option, but it works best when it is integrated into comprehensive psychiatric care. Depression rarely affects only mood. It can disrupt sleep, concentration, relationships, energy, work performance, and physical health. A treatment approach that only focuses on one symptom often falls short.
That is why many patients benefit from combining Spravato with medication management, therapy, and regular follow-up. If anxiety, ADHD symptoms, trauma, or mood instability are part of the picture, those factors should be addressed too. Personalized care improves the chances that symptom relief turns into real-life progress.
At a psychiatric practice like Alpha Minds Services, that integrated model is especially valuable because it helps patients move from evaluation to targeted treatment without feeling lost between providers.
What results patients can expect
Some patients report noticeable relief within the first few treatments. Others improve more gradually over several weeks. Common early changes include less emotional heaviness, improved motivation, better sleep, or a reduced sense of hopelessness. For patients with severe depression, even small shifts can be meaningful.
Still, no ethical provider should promise the same outcome for everyone. Spravato is highly effective for some patients and less effective for others. The question is not whether it is a miracle treatment. The question is whether it offers a medically sound next step when previous treatments have not done enough.
Measuring success also goes beyond mood scores. Clinicians look at whether you are functioning better, engaging more with daily life, and experiencing more stable improvement over time. Those are the outcomes that matter most.
Side effects and safety considerations
The most common side effects include dissociation, dizziness, nausea, sedation, headache, altered taste, and temporary increases in blood pressure. In most cases, these effects happen shortly after dosing and improve during the monitoring period.
Because Spravato has specific safety requirements, it is only available through a restricted program that ensures it is administered and observed in a certified healthcare setting. That structure helps protect patients while giving them access to an advanced treatment option.
Patients should always be open with their psychiatrist about medical history, pregnancy status, substance use, and all current medications. Safe treatment depends on complete information. If something changes during the course of care, the treatment plan may need to change too.
For people in Saginaw and surrounding communities who have been living with stubborn depression, asking about Spravato can be more than a medication question. It can be the start of a different path – one built around careful evaluation, expert supervision, and the possibility that feeling better is still within reach.